Document is current
Any future updates will be listed below
-
Authors
Ferrara, Anne Lise https://orcid.org/0000-0003-1839-8873
Cristinziano, Leonardo https://orcid.org/0000-0002-7835-2212
Petraroli, Angelica https://orcid.org/0000-0001-5700-7164
Bova, Maria https://orcid.org/0000-0002-7655-0696
Gigliotti, Maria Celeste https://orcid.org/0000-0001-6814-8237
Marcella, Simone https://orcid.org/0000-0003-4844-5810
Modestino, Luca https://orcid.org/0000-0003-2063-7124
Varricchi, Gilda https://orcid.org/0000-0002-9285-4657
Braile, Mariantonia https://orcid.org/0000-0002-3067-217X
Galdiero, Maria Rosaria https://orcid.org/0000-0002-8086-9130
Spadaro, Giuseppe https://orcid.org/0000-0001-7889-425X
Loffredo, Stefania https://orcid.org/0000-0002-5871-1898
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A. (IIR-ITA-002138)
Università degli Studi di Napoli Federico II
- License Information
-
More Information
Article History
Accepted: 13 January 2021
First Online: 29 May 2021
Compliance with Ethical Standards
:
: The authors declare that they have no competing interests.
: The Ethical Committee of the University of Naples Federico II (protocol number: 300/18) approved that plasma of C1-INH-HAE, and healthy controls obtained during routine diagnostics could be used for research investigating the physiopathology of hereditary angioedema.
: Written informed consent was obtained from patients in according to the principles expressed in the Declaration of Helsinki.
